O ver the past decade, there has been a proliferation of clinical practice guidelines (CPGs) in the field of endocrinology and a coincidental increased interest in transparency regarding relationships between physicians and pharmaceutical companies. CPGs are generally designed to standardize patient care regarding the diagnosis and/or treatment of a particular condition or disease. Although CPGs strive to be evidence based when possible, there are many unanswered questions for which solid evidence is lacking. Given that many recommendations are based upon low-quality evidence, the objectivity of the authors of CPGs is particularly important because their recommendations have the potential to strongly influence how a particular treatment or medication is prescribed. Most of the financial conflicts of interest (COIs) are linked to pharmaceutical companies seeking to promote expensive, newer branded medications that contribute to the high cost of medications and/or health insurance. The presence of financial COIs among authors of CPGs has been linked to treatment recommendations. For example, antidepressants were more likely to be recommended as a first-line intervention for mild depression in CPGs whose authors and/or chairs had relevant financial ties to drug manufacturers of antidepressants (1) . Similarly, in a study of 10 authors of review articles and commentaries relating to postmenopausal hormone therapy, articles promoting the hormone therapy were 2.4 times as likely to have been written by authors with COIs than by authors without (2) .
The past decade has witnessed a major shift in the reporting of COIs in CPGs sponsored by medical organizations and societies. For example, in a survey of 44 CPGs published between 1991 and 1999, only 5% (2 of 44) declared authors' potential COIs (3) . Similarly, there was no disclosure of financial associations of the authors of three major CPGs published by the American Psychiatric Association between 2000 and 2004 (4). In 2011, the National Academy of Medicine (formerly the Institute of Medicine) published a report that included a set of recommendations to promote trustworthy CPGs "based on explicit and transparent processes that minimize distortions, biases and conflicts of interest" (5) . In a study of 114 randomly selected guidelines from the National Guideline Clearinghouse published from 2006 to 2011 (before the National Academy of Medicine report), the median number of National Academy of Medicine selected recommendations satisfied was only 8 of 18 (6) .
Historically, relationships between physicians and the pharmaceutical industry have been commonplace. In a survey of 1662 physicians among six specialties conducted in 2003 and 2004, 94% reported some relationship, including food in the workplace (83%), medication samples (78%), meeting reimbursements (35%), consulting payments (18%), speakers' payments (16%), and service on advisory boards (9%) (7) . Among authors of CPGs, 87% reported relationships with the pharmaceutical industry, including speaker honoraria (64%), research funding (58%), travel funding/honoraria (53%), educational program support (51%), consultancies/employment (38%), or equities (6%) (3). Fifty-nine percent of these authors had financial ties with companies whose medications were considered in the guideline they had authored.
Studies examining the perceptions of physicians have often found that many do not believe that gifts can influence their behavior (8) . For example, in a survey of 192 authors of 44 CPGs, 7% believed that their relationships with industry influenced their recommendations, whereas 19% believed that this was the case for their colleagues (3). Nonetheless, objective data have shown that a single meal (mean value, $12 to $18) can influence prescribing patterns.
In a study of .200,000 physicians using Open Payment (OP) data, those who received a single meal promoting a branded drug of interest had higher rates of prescribing the promoted drug (ORs ranging from 1.2 to 2.2) than physicians receiving no target meals (9) . Physicians who received meals promoting a target drug on at least 4 days in a 5-month period prescribed the drug 1.8 to 5.4 times the rate of those who did not receive any meals (9) .
In 2009, the US Congress passed the Physician Payments Sunshine Act to provide transparency regarding financial ties between pharmaceutical companies and physicians. Under this act, the Centers for Medicare & Medicaid Services maintains the OP Program, a public online database that lists individual payments .$10 by pharmaceutical and device companies to individual physicians and institutions. According to 2016 reported data, 1481 companies reported $8.18 billion in payments to 631,000 physicians and/or 1146 teaching hospitals (10) .
Methods
We examined CPGs published in The Journal of Clinical Endocrinology & Metabolism from January 2010 to September 2017 for which the primary sponsor was the Endocrine Society. The Endocrine Society has a broad national and international membership and a high number of CPGs and is based in the United States, where the OP Program exists. We examined CPGs listed on the web site of the organization (www.endocrine.org/guidelinesand-clinical-practice/clinical-practice-guidelines). We focused on treatment and diagnostic guidelines that provided recommendations regarding medications, specialized diagnostic tests, and/or diabetes technologies. In cases where guidelines had been revised, only the most recent version was included. We specifically focused on relevant COIs in which pharmaceutical and device companies manufactured drugs or products pertinent to a specific CPG of the author.
Defining a relevant COI can be a challenge when a medication is in the early stage of development and has not yet been marketed. We erred on the side of including COIs of products not yet approved because CPGs can promote a certain class of medications. Nonetheless, some COIs were likely not captured when the products were in the early stages of development with little information available online. Given the various natures of financial COIs, we grouped them broadly into research and nonresearch categories (consultancies, honoraria, travel, food) because this is how payments are reported in the OP database. Current policies regarding COIs were ascertained by reading the 2017 CPGs and through e-mail queries with staff at the Endocrine Society.
We tabulated self-reported financial relationships with pharmaceutical and device companies for each author of each guideline. We specifically focused on relevant COIs in which pharmaceutical and device companies manufactured drugs or products pertinent to a specific CPG of the author. Business entities were evaluated to see whether they manufactured endocrine drugs or diabetes devices. To provide an overall sense of the relationships between authors of CPGs and industry, we also collected data on any financial relationships with any pharmaceutical and device companies.
We collected data on payments to all US authors of endocrine CPGs from the entire available reporting period of the OP Program (2013 to 2016). The payments include food and beverages, travel expenses, speaking fees, honoraria, consulting fees, and research activities. The sum of all research and nonresearch payments from industry to all US authors of a particular CPG was calculated.
The statistical analysis (calculating sums, means, medians) was performed with Microsoft Excel (Microsoft Corporation, Redmond, WA).
Relevant COIs
COI information from the 26 CPGs is presented by endocrine subspecialty in Table 1 . Many of the CPGs were cosponsored by other organizations, such as the Pediatric Endocrine Society and the European Society of Endocrinology. The number of authors for each CPG ranged from 5 to 13, with a mean of 8. There were a total of 169 authors, some of whom served on multiple CPGs.
The breakdown of the authors was 113 from the United States and 56 international.
Regarding relevant COIs to their particular CPG, 62% (16 of 26) of chairs disclosed one, and 42% of authors selfreported relevant nonresearch COIs. Self-reported research COIs were not clearly specified in 16 of the CPGs of the Endocrine Society, depending on the year of publication. All but one CPG had at least one author who self-reported any financial COI with a pharmaceutical and/ or device company. Any pharmaceutical and/or device company COIs were self-reported by 46% of authors.
Payments to Authors of CPGs
Of the 113 authors from the United States, 84 had a payment listed on the OP database. The OP financial information presented in Table 1 is the sum of all payments to all US authors of a particular CPG from 2013 to 2016. Payments to 84 US authors totaled $5.5 million for (10). We could not ascertain the percentage of authors with self-disclosed research COIs because the nature of COIs was not specified in 16 of the 26 CPGs. The OP program includes only payments to physicians in the United States and did not capture financial COIs for the 56 international authors. The total dollars reported is therefore an underestimate of the true monetary value. Although the financial totals from the OP program often did not overlap with the time period when the CPG was being developed or published, they were calculated to provide an overall sense of the magnitude of the payments from industry to authors of CPGs. The data from the OP program is also incomplete because some payments could not be reconciled and because many physicians had not logged into the system to verify the accuracy of the payments attributed to them (37) .
Not surprisingly, the number of COIs and the amount of monetary payments were often related to the topic of the CPG and whether newer branded medications were available. For example, the nonresearch and research funding to authors of the gender dysphoria CPG was comparatively low because newer and expensive branded medications are not used to treat this condition.
The objective data from the OP program is a valuable tool for transparency because some authors of CPGs fail to disclose relevant ties to industry. An analysis of 40 authors from three CPGs published by the American Academy of Dermatology in 2013 to 2016 demonstrated that 55% of the disclosure statements were discrepant from OP data and that 15% (6 of 40) of authors reported no COIs yet received significant industry payments (38) . Although our study was not designed to compare every payment from the OP database with self-disclosures, we did come across several noticeable discrepancies. For example, an author on one CPG reported no financial interests, whereas the OP data showed that he received .$200,000 from manufacturers of products relevant to the CPG.
COI Recommendations From the National Academy of Medicine
The adherence of the Endocrine Society to seven recommendations of the National Academy of Medicine (formerly the Institute of Medicine) is summarized in Table 2 . The Endocrine Society partially follows the recommendations to limit COIs among authors and its policies have evolved and become more rigorous over time, as described in the accompanying commentary by McCartney and Rosen (39) . More transparency is needed in the methods sections of the CPGs describing their development. The Endocrine Society does not accept outside funding for CPG development, although part of its budget comes from pharmaceutical companies. Most of the CPGs of the Endocrine Society did not provide details on the nature of the conflict (e.g., consultancy, speaker honorarium, research). The majority of the CPGs of the Endocrine Society divided author disclosures into two broad categories: financial or business/ organizational interests and significant financial interest or leadership position. Although all 26 endocrine CPGs had a section for author disclosures, there was virtually no information for readers regarding if and/or how COIs were managed. The National Academy of Medicine could update its recommendations to include effective strategies to manage COIs when they are present (i.e., restricting conflicted members from certain roles).
What Readers Should Know About CPGs
Readers of CPGs are looking for unbiased and trustworthy recommendations that are based on what is best When selecting authors for CPGs, one should acknowledge that experts will likely have more potential conflicts and disclosures than nonexperts because those considered experts often have performed funded research in the area. Although some might argue that COIs are unavoidable when selecting experts to author CPGs, several CPGs in prestigious journals have done so. For example, no COIs were reported among all four authors of a diabetes CPG sponsored by the American College of Physicians (40) .
Readers should also be aware of eight red flags identified by Lenzer et al. (41) that may compromise the quality and trustworthiness of CPGs: sponsor(s) is a professional society that receives substantial industry funding; sponsor is a proprietary company or is undeclared or hidden; committee chair(s) has any financial conflict; multiple panel members have any financial conflict; there is any suggestion of committee stacking that would preordain a recommendation regarding a controversial topic; there is no or limited involvement of an expert in methodology in the evaluation of evidence; there is no external review; and no nonphysician experts/patient representative/community stakeholders are included (41) .
Summary
Relevant financial COIs are commonplace among authors of endocrine CPGs. The Endocrine Society partially adheres to the National Academy of Medicine's COI recommendations. To enable readers to fully appreciate COIs among authors of their CPGs, endocrine organizations and journal editors could do a better job of describing their processes of CPG development, disclosing the specific types of COIs for each author, and describing if and how COIs were managed. To promote CPGs that are as objective as possible, leaders of professional societies and journal editors should regularly assess whether their policies are as effective as they can be.
